Pharma and healthcare: sector news on Sunday 25 October 2026
Average tone +3.8 (positive) across 5 companies with relevant coverage, from 29 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +10.0 | 16 | Coverage was dominated by strong Phase III results at ESMO, with Imfinzi combinations lowering the risk of death for patients with bladder cancer and with the small cell form of lung cancer. |
| GSK | +2.0 | 6 | Coverage was split between positive trial data for Jemperli and mo-rez in ovarian cancer, and a $2.2B Zantac legal charge alongside R&D setbacks. |
| Haleon | +5.7 | 3 | Coverage was led by a report of free cash flow rising 21.1% to $3.1B, which leans positive. |
| Smith & Nephew | −2.0 | 3 | Coverage centres on a reported collapsed J&J deal involving Smith & Nephew, which leans negative. |
| Convatec | +3.0 | 1 | Coverage was a single Simply Wall Street piece asking whether supplier awards could change the narrative around Convatec's share price. |
Strongest stories in the sector
- +10.0 Company announces strong Phase III result for Imfinzi combination.
- +10.0 Phase III result with 58% death risk reduction for Imfinzi.
- +10.0 Imfinzi combination shows strong survival benefit in lung cancer trial.
- +10.0 Company announces strong perioperative bladder cancer trial results.
- +10.0 Pairing cut death risk by 58% in lung cancer (small cell).
- +10.0 Perioperative Imfinzi cut recurrence 49% and death 42% in bladder cancer.
- +10.0 Major outlet reports strong survival benefit for combination including Imfinzi.
- +10.0 Unprecedented survival benefit for combination with Imfinzi; Amgen-led release.
- +10.0 Positive interim phase II results for Jemperli monotherapy.
- +9.7 Free cash flow reported up 21.1% to $3.1B, strong financial result.
- +9.2 Combination extends lung cancer survival.
- +8.3 Huge survival benefit, though credit centres on Amgen's drug.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.